Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Immunotec, Lophius Ink Licensing Deals for Development of T-cell-based Assays

NEW YORK (GenomeWeb News) – Oxford Immunotec and Lophius Biosciences said today that they have signed agreements providing each other access to certain intellectual property.

As a result, Oxford Immunotec will be able to develop novel T-cell-based assays using Lophius' Urea technology and commercialize them in certain geographies. Lophius, which announced last week that it raised $5.3 million, can develop and commercialize novel T-cell-based assays under a license from Oxford Immunotec for its T-Spot technology.

Financial and other terms of the deals were not disclosed.

"We believe that Lophius' Urea technology has distinct advantages over conventional methods of designing and producing antigens for T-cell-based diagnostic systems," Peter Wrighton-Smith, CEO of Oxford Immunotec, said in a statement. "We are looking forward to combining Lophius' technology with our own, to develop and launch innovative new assays for infectious and immunological disease."

Based in Oxford, UK, Oxford Immunotec develops immunology-focused diagnostics. Lophius, headquartered in Regensburg, Germany, develops T-cell-based tests for diagnostic purposes and as possible therapy controls in transplantation, infection, and autoimmune diseases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.